Asahi Life Asset Management CO. LTD. Buys Shares of 1,065 Bio-Rad Laboratories, Inc. (NYSE:BIO)

Asahi Life Asset Management CO. LTD. bought a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 1,065 shares of the medical research company’s stock, valued at approximately $350,000.

Other hedge funds have also bought and sold shares of the company. Metis Global Partners LLC increased its stake in shares of Bio-Rad Laboratories by 4.4% in the fourth quarter. Metis Global Partners LLC now owns 712 shares of the medical research company’s stock worth $234,000 after buying an additional 30 shares during the period. Avior Wealth Management LLC increased its stake in shares of Bio-Rad Laboratories by 3.3% in the third quarter. Avior Wealth Management LLC now owns 999 shares of the medical research company’s stock worth $334,000 after buying an additional 32 shares during the period. UMB Bank n.a. increased its stake in shares of Bio-Rad Laboratories by 41.6% in the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after buying an additional 32 shares during the period. Tokio Marine Asset Management Co. Ltd. increased its stake in shares of Bio-Rad Laboratories by 3.9% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company’s stock worth $296,000 after buying an additional 34 shares during the period. Finally, CIBC Asset Management Inc increased its stake in shares of Bio-Rad Laboratories by 5.0% in the fourth quarter. CIBC Asset Management Inc now owns 713 shares of the medical research company’s stock worth $234,000 after buying an additional 34 shares during the period. 65.24% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on BIO. Wells Fargo & Company decreased their target price on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. StockNews.com downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $395.20.

Bio-Rad Laboratories Stock Down 0.4 %

Shares of Bio-Rad Laboratories stock opened at $264.60 on Friday. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. The company’s fifty day simple moving average is $327.02 and its two-hundred day simple moving average is $332.57. The company has a market cap of $7.41 billion, a P/E ratio of -4.07 and a beta of 0.90. Bio-Rad Laboratories, Inc. has a 12-month low of $262.11 and a 12-month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.